Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001583435 | SCV001812360 | uncertain significance | not provided | 2020-10-26 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001832797 | SCV003459131 | uncertain significance | Nemaline myopathy 2 | 2021-10-19 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with proline, which is neutral and non-polar, at codon 6673 of the NEB protein (p.His6673Pro). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with NEB-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004952993 | SCV005451786 | uncertain significance | Inborn genetic diseases | 2024-07-16 | criteria provided, single submitter | clinical testing | The c.14915A>C (p.H4972P) alteration is located in exon 103 (coding exon 101) of the NEB gene. This alteration results from a A to C substitution at nucleotide position 14915, causing the histidine (H) at amino acid position 4972 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001832797 | SCV002084103 | uncertain significance | Nemaline myopathy 2 | 2020-06-14 | no assertion criteria provided | clinical testing |